Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.
Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.
The proportion of people with rheumatic and musculoskeletal diseases experiencing severe COVID-19 has declined since the beginning of the pandemic, particularly during the recent Omicron wave, US researchers report.